BioSig Technologies’ (BSGM +0.7%) and its subsidiary ViralClear Pharmaceuticals have partnered
with Catalent to work on the development of a potential treatment for
adults with advanced COVID-19 under which it would develop two oral
dosage forms of ViralClear’s broad-spectrum anti-viral agent,
merimepodib.
Steve King, COO ViralClear, said that “ViralClear
is committed to using U.S.-based contract development and manufacturing
organizations for the development and commercialization of merimepodib.”
https://seekingalpha.com/news/3585119-viralclear-partners-catalent-on-potential-covidminus-19-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.